196 related articles for article (PubMed ID: 2440124)
1. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
[TBL] [Abstract][Full Text] [Related]
2. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
van Giezen JJ; Minkema J; Bouma BN; Jansen JW
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
4. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
[TBL] [Abstract][Full Text] [Related]
5. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization.
Devine DV; Bishop PD
Semin Thromb Hemost; 1996; 22(5):409-13. PubMed ID: 8989824
[TBL] [Abstract][Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activation and lysis of blood clots induced by cells in vitro.
Knox P; Crooks S
J Cell Physiol; 1988 Jun; 135(3):467-73. PubMed ID: 2456288
[TBL] [Abstract][Full Text] [Related]
9. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
10. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
11. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
Reed GL; Matsueda GR; Haber E
Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
[TBL] [Abstract][Full Text] [Related]
12. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
13. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Lee SC; Jackson KW; Tae WC; Schwartzott DG; McKee PA
Thromb Haemost; 1998 Oct; 80(4):637-44. PubMed ID: 9798984
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
16. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
17. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
18. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
Ogloblina OG; Saburova OS; Semenova OA; Belova LA
Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
[TBL] [Abstract][Full Text] [Related]
19. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
20. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
